GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OncoCyte Corp (NAS:OCX) » Definitions » PB Ratio

OncoCyte (OncoCyte) PB Ratio : 1.89 (As of Jun. 24, 2024)


View and export this data going back to 2015. Start your Free Trial

What is OncoCyte PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-06-24), OncoCyte's share price is $2.65. OncoCyte's Book Value per Share for the quarter that ended in Mar. 2024 was $1.40. Hence, OncoCyte's PB Ratio of today is 1.89.

The historical rank and industry rank for OncoCyte's PB Ratio or its related term are showing as below:

OCX' s PB Ratio Range Over the Past 10 Years
Min: 0.48   Med: 1.97   Max: 13.09
Current: 1.89

During the past 11 years, OncoCyte's highest PB Ratio was 13.09. The lowest was 0.48. And the median was 1.97.

OCX's PB Ratio is ranked worse than
50.98% of 204 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.995 vs OCX: 1.89

During the past 12 months, OncoCyte's average Book Value Per Share Growth Rate was -78.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -36.50% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 1.20% per year.

During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of OncoCyte was 103.30% per year. The lowest was -41.00% per year. And the median was -14.90% per year.

Back to Basics: PB Ratio


OncoCyte PB Ratio Historical Data

The historical data trend for OncoCyte's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte PB Ratio Chart

OncoCyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.16 4.93 3.07 1.11 1.01

OncoCyte Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.11 0.87 0.69 1.01 2.09

Competitive Comparison of OncoCyte's PB Ratio

For the Diagnostics & Research subindustry, OncoCyte's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoCyte's PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, OncoCyte's PB Ratio distribution charts can be found below:

* The bar in red indicates where OncoCyte's PB Ratio falls into.



OncoCyte PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

OncoCyte's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=2.65/1.401
=1.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


OncoCyte  (NAS:OCX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


OncoCyte PB Ratio Related Terms

Thank you for viewing the detailed overview of OncoCyte's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoCyte (OncoCyte) Business Description

Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.
Executives
John Peter Gutfreund other: Former Director 767 5TH AVENUE, 44TH FLOOR, NEW YORK NY 10153
Alfred D Kingsley director 150 E 57TH STREET, NEW YORK NY 10022
Pura Vida Investments, Llc 10 percent owner 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Broadwood Partners Lp 10 percent owner BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Andrew Arno director C/O MERRIMAN CURHAN FORD GROUP, INC., 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Josh Riggs officer: Interim CEO 15 CUSHING, IRVINE CA 92618
Lou Silverman director
James Yang Liu officer: Controller, PAO C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
Andrew J. Last director 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Jennifer L. Carter director C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ronald Asbury Andrews director 5791 VAN ALLEN WAY, CARLSBAD CA 92008
Melinda Griffith director 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Anish M. John officer: SVP, Finance, and Interim CFO C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618
Li Yu officer: VP Cntrllr/Prncpl Acctng Offcr 120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660
Efrem Kamen 10 percent owner C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011